Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04563520 · ClinicalTrials.gov registry record · Phase 3
SAFE Study: Safety of aPCC Following Emicizumab Prophylaxis
A Phase 3 study of Hemophilia A, sponsored by Emory University.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 5
- Enrollment target
- 2
- Study locations
NCT04563520 is a Phase 3 study of Hemophilia A that is actively recruiting participants, run by Emory University. The registered enrollment target is 5 participants, below the 91-participant average among 42 other Hemophilia A trials with a reported enrollment target (95% lower). The trial reports 2 study locations across 1 state.
The verdict
NCT04563520, a Phase 3 study of Hemophilia A, is actively recruiting participants, sponsored by Emory University.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 5 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of the aPCC-emicizumab safety study is to investigate the hemostatic efficacy as measured by thrombin generation, of a low personalized dose of aPCC (FEIBA) in children and adults with hemophilia A and inhibitors on emicizumab prophylaxis.
Conditions Studied
Interventions
- DRUG Emicizumab
- DRUG FEIBA
- DRUG rFVIIa
Study Locations (2)
Georgia
- Children's Healthcare of Atlanta - Atlanta
- Emory University Hospital - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2026-03 |
| Est. Completion | 2027-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04563520
The ClinicalTrials.gov registry entry for NCT04563520 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 91-participant average among 42 other Hemophilia A trials with a reported enrollment target (95% lower). The listed sponsor is Emory University, which has 1,208 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hemophilia A appearing as the primary indexed condition, and to 3 interventions - of which Emicizumab is the first listed.
NCT04563520 reports 2 study locations spanning 1 distinct geographic area - top geographies include Georgia.
Frequently Asked Questions
What is clinical trial NCT04563520 about?
NCT04563520 is a clinical study titled "SAFE Study: Safety of aPCC Following Emicizumab Prophylaxis". The purpose of the aPCC-emicizumab safety study is to investigate the hemostatic efficacy as measured by thrombin generation, of a low personalized dose of aPCC (FEIBA) in children and adults with hemophilia A and inhibitors on emicizumab prophylaxis.
What is the current status of trial NCT04563520?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 5 participants. The study started on 2026-03. Estimated completion is 2027-03.
What conditions does trial NCT04563520 study?
This clinical trial studies the following conditions: Hemophilia A.
What interventions are being tested in trial NCT04563520?
The interventions under investigation include: Emicizumab (DRUG), FEIBA (DRUG), rFVIIa (DRUG).
Who is sponsoring clinical trial NCT04563520?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04563520 being conducted?
This trial has 2 study locations across Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hemophilia A
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Clinical Trial of Study Medicine (Marstacimab) in Pediatric Patients With Hemophilia A or Hemophilia B
RECRUITING · Phase 3
-
Open-Label Extension Study of Marstacimab in Hemophilia Participants With or Without Inhibitors
RECRUITING · Phase 3
-
Safety and Effectiveness of Giroctocogene Fitelparvovec or Fidanacogene Elaparvovec in Patients With Hemophilia A or B Respectively
RECRUITING · Phase 3
-
Long-term Safety and Efficacy of Efanesoctocog Alfa (BIVV001) in Previously Treated Patients With Hemophilia A
ACTIVE NOT RECRUITING · Phase 3
-
Study to Evaluate the Efficacy and Safety of PF-07055480 / Giroctocogene Fitelparvovec Gene Therapy in Moderately Severe to Severe Hemophilia A Adults
ACTIVE NOT RECRUITING · Phase 3
-
A Study of Emicizumab Administered Subcutaneously (SC) in Pediatric Participants With Hemophilia A and Factor VIII (FVIII) Inhibitors
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.